<DOC>
	<DOC>NCT01382407</DOC>
	<brief_summary>The hypothesis of this study is that patients who suffered from acne vulgaris during adolescence are at greater risk of developing acneiform skin rash due to cetuximab.</brief_summary>
	<brief_title>Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab</brief_title>
	<detailed_description>The hypothesis of this study is that patients who suffered from acne vulgaris during adolescence are at greater risk of developing acneiform skin rash due to cetuximab</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Age above 18 years. Histology or cytology proven KRASWT mCRC. Performance status ≤3 (Eastern Cooperative Oncology Group [ECOG] classification) Life expectancy of more than 12 weeks. Written informed consent. In women of childbearing potential, appropriate contraceptive measures must be used during treatment with cetuximab and for 6 months following the last dose of cetuximab. Past systemic immune therapy for disease other than cancer. Past immune or other target therapy for cancer (not including bevacizumab). Presence of acne or acneiform rash prior to starting treatment with cetuximab. Patients with treatment plan of cetuximab and capecitabine combination. For female patients: the patient is pregnant or lactating.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>skin rash reaction</keyword>
	<keyword>ERBITUX® (cetuximab)</keyword>
	<keyword>acne</keyword>
</DOC>